Brain cancer continues to be a major global health burden. Patients often experience persistent headaches, seizures, memory loss, and difficulty thinking, which significantly affect quality of life.
Glioblastoma (GBM) is the most common and deadliest type of brain tumor. It grows rapidly, infiltrates normal brain tissue, and is very difficult to treat. Standard care includes surgery followed by radiation and chemotherapy, but these treatments rarely provide long-term control. Even after aggressive therapy, most patients relapse. One major obstacle is the blood–brain barrier, which blocks many anti-cancer drugs from reaching the tumor, limiting treatment choices.
Scientists are actively exploring new treatment strategies. One promising direction focuses on nuclear receptors (NRs), a group of proteins that regulate gene expression in response to hormones, vitamins, and other molecules. These receptors are essential for normal cell growth and metabolism, but changes in their activity can contribute to cancer.
Recent research suggests that gut microbes may also influence brain cancer. Certain microbial metabolites can act as ligands for nuclear receptors, potentially affecting tumor development and response to treatment. This reveals a possible gut–brain–tumor connection.
Several nuclear receptors—such as androgen receptors, estrogen receptors, glucocorticoid receptors, and PPARs—are often found in higher levels or altered forms within brain tumors. Researchers are studying drugs that either activate or block these receptors to slow tumor progression, boost treatment effectiveness, and reduce side effects. Targeting these receptors with specially designed small molecules may help overcome drug resistance and improve delivery past the blood–brain barrier.
As research advances, nuclear receptors are increasingly recognized as promising targets for precision therapies, offering new hope for patients with GBM and other brain cancers.